CIP
OMED

Convergence Investment Partners’s OncoMed Pharmaceuticals, Inc. OMED Stock Holding History

Convergence Investment Partners’s Portfolio OMED Stock Details OMED Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-111,945
Closed -$2.12M – 457
2014
Q3 		$2.12M Buy
111,945
+83,230
+290% +$1.67M 0.29% 132
2014
Q2 		$669K Buy
+28,715
New +$709K 0.09% 284

Other funds holding OMED

SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
AC
Apex Capital Orinda, California $938M AUM 4.67% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Convergence Investment Partners's OMED Position: Q4 2014 in Review

Convergence Investment Partners sold out of OncoMed Pharmaceuticals, Inc. (OMED) in Q4 2014, closing a stake of 111,945 shares — an estimated $2.12M sold.

Convergence Investment Partners first reported a position in OMED in Q2 2014 and held it in 2 quarters. The position peaked at $2.12M in Q3 2014. 68 funds tracked by Wall St. Rank hold OMED as of Q4 2014.

  • Convergence Investment Partners reported no remaining OncoMed Pharmaceuticals, Inc. position as of Q4 2014 after selling out during the quarter.
  • Convergence Investment Partners sold 111,945 OncoMed Pharmaceuticals, Inc. shares in Q4 2014, an estimated $2.12M.
  • Convergence Investment Partners first reported a position in OncoMed Pharmaceuticals, Inc. in Q2 2014 and held it in 2 quarters.
  • Convergence Investment Partners's OncoMed Pharmaceuticals, Inc. position peaked at $2.12M in Q3 2014.
  • 68 funds tracked by Wall St. Rank held OncoMed Pharmaceuticals, Inc. as of Q4 2014.

Based on Convergence Investment Partners's 13F filing for Q4 2014, filed 11 Feb 2015.